期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Inflammatory bowel disease:Epidemiology,pathology and risk factors for hypercoagulability 被引量:19
1
作者 Danuta Owczarek Dorota Cibor +2 位作者 Mikolaj K Glowacki Tomasz Rodacki Tomasz Mach 《World Journal of Gastroenterology》 SCIE CAS 2014年第1期53-63,共11页
Hypercoagulability observed in patients with inflammatory bowel diseases (IBD) may lead to thromboembolic events (TE), which affect the venous and arterial systems alike and are an important factor in patients&#x0... Hypercoagulability observed in patients with inflammatory bowel diseases (IBD) may lead to thromboembolic events (TE), which affect the venous and arterial systems alike and are an important factor in patients&#x02019; morbidity and mortality. The risk of TE in IBD patients has been demonstrated to be approximately three-fold higher as compared to the general population. The pathogenesis of thrombosis in IBD patients is multifactorial and not fully explained. The most commonly listed factors include genetic and immune abnormalities, disequilibrium between procoagulant and anticoagulant factors, although recently, the role of endothelial damage as an IBD-triggering factor is underlined. Several studies report that the levels of some coagulation enzymes, including fibrinogen, factors V, VII, VIII, active factor XI, tissue factor, prothrombin fragment 1 + 2 and the thrombin-antithrombin complex, are altered in IBD patients. It has been demonstrated that there is a significant decrease of tissue plasminogen activator level, a marked increase of plasminogen activator inhibitor type 1 and thrombin-activable fibrinolysis inhibitor, a significantly lower level of antithrombin III and tissue factor pathway inhibitor. IBD patients have been also observed to produce an increased amount of various anticoagulant antibodies. Hyperhomocysteinemia, which is a potential risk factor for TE was also observed in some IBD patients. Further studies are necessary to assess the role of coagulation abnormalities in IBD etiology and to determine indications for thromboprophylactic treatment in patients at high risk of developing TE. 展开更多
关键词 Crohn’ s disease Hypercoagulation Risk factors Thrombosis Ulcerative colitis
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部